BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17727474)

  • 1. Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
    Stewart CJ; Brennan BA; Crook ML; Russell P
    Histopathology; 2007 Sep; 51(3):313-21. PubMed ID: 17727474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomeruloid peritoneal implants in ovarian serous borderline tumours--distinction between invasive and non-invasive implants and pathogenesis.
    Lee ES; Leong AS; Kim IS; Kim YS; Lee JH; Cho HY
    Histopathology; 2009 Nov; 55(5):505-13. PubMed ID: 19912356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological evaluation on ovarian serous borderline tumours and their implants].
    Guo L; Lian L; Liu T
    Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):287-90. PubMed ID: 9206182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
    Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calretinin, CD34, and alpha-smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary.
    Lee ES; Leong AS; Kim YS; Lee JH; Kim I; Ahn GH; Kim HS; Chun YK
    Mod Pathol; 2006 Mar; 19(3):364-72. PubMed ID: 16415795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.
    Srinivasamurthy BC; Kulandai Velu AR; Krishnan N; Patil AS
    J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum.
    Hinson SA; Silva EG; Pinto K
    Ann Diagn Pathol; 2013 Jun; 17(3):302-4. PubMed ID: 22921726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
    Roh MH; Kindelberger D; Crum CP
    Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ovarian serous tumors of limited malignancy and invasive peritoneal implants. Review of the literature].
    Fondrinier E; Seince N; Verriele V; Lorimier G; Gamelin E
    Contracept Fertil Sex; 1999 Nov; 27(11):780-4. PubMed ID: 10609410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
    McKenney JK; Soslow RA; Longacre TA
    Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral micropapillary serous carcinoma of the ovary: a case report.
    Gupta R; Singh S; Nigam S
    Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian psammocarcinoma with peritoneal implants.
    Cobellis L; Pezzani I; Cataldi P; Bome A; Santopietro R; Petraglia F
    Eur J Obstet Gynecol Reprod Biol; 2003 Apr; 107(2):217-9. PubMed ID: 12648875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.